Efficacy News and Research

RSS
Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Optivia, UCSF receive SBIR grant to develop transporter-based assay system

Optivia, UCSF receive SBIR grant to develop transporter-based assay system

Color of tablet appears to be integral component for OTC product

Color of tablet appears to be integral component for OTC product

New mathematical method predicts dominant strain of influenza virus

New mathematical method predicts dominant strain of influenza virus

New mechanism breaks drug resistance in ovarian cancer

New mechanism breaks drug resistance in ovarian cancer

Fisetin slows onset of motor problems, delays death in three models of Huntington's disease: Study

Fisetin slows onset of motor problems, delays death in three models of Huntington's disease: Study

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Bayer presents results from Phase III ROCKET AF trial for atrial fibrillation at American Heart Association

Celladon presents data on Phase 2 CUPID clinical trial for advanced heart failure at   American Heart Association

Celladon presents data on Phase 2 CUPID clinical trial for advanced heart failure at American Heart Association

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda

Oramed presents ORMD-0801 Phase IIb results for Type II diabetes at Annual Meeting in Bethesda

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

High-dose prescription omega-3 does not reduce recurrence of atrial fibrillation

High-dose prescription omega-3 does not reduce recurrence of atrial fibrillation

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents

No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia

No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia

World's first remote heart procedure using robotic arm alongside 3-D mapping

World's first remote heart procedure using robotic arm alongside 3-D mapping

Science and precedent do not support biosimilar approach for plasma protein therapies

Science and precedent do not support biosimilar approach for plasma protein therapies

Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal

Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal

Scios announces results of ASCEND-HF trial for ADHF treatment

Scios announces results of ASCEND-HF trial for ADHF treatment

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.